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We are entering a new era in the treatment of hepatitis C virus (HCV) infection and almost all patient
groups in high-income countries have the potential to be cured with all-oral, highly potent combinations
of direct-acting antiviral drugs. Soon the main barrier to curing hepatitis C, even in wealthy countries,
will be the high price of these all-oral regimens. The gulf between the advances in HCV drug development
and access to treatment for individual patients will be even greater in low- and middle-income countries
(LMIC) where 80% of the global burden of HCV infection and mortality exists. Ensuring that people in
LMIC have access to regimens against HCV will require a similar level of advocacy and public–private
partnerships as has transformed the control of other global diseases such as HIV. Numerous challenges
will need to be overcome. These include improving low-cost diagnostic tests, especially in sub-Saharan
Africa where the false-positive rate is unacceptably high, reducing iatrogenic spread of HCV, addressing
transmission among people who inject drugs (PWID), and ensuring affordable access to antiviral treat-
ment for all people living with HCV infection in LMIC. This article forms part of a symposium in
Antiviral Research on ‘‘Hepatitis C: next steps toward global eradication.’’
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In the last few years, we have seen advances in hepatitis C drug
development that rival those for any other disease in medical his-
tory. We are now able to cure hepatitis C virus (HCV) infection in
most patients with highly effective, safe and tolerable combina-
tions of oral direct-acting antivirals (DAAs) taken for 8–24 weeks.
Eradication of hepatitis C is being discussed for the ﬁrst time,
although actual implementation will be challenging even in
high-income countries such as the United States (Edlin and
Winkelstein, 2014). In recognition of this rapid evolution in HCV
drug development, the World Health Organization (WHO) issued
its ﬁrst guidelines addressing HCV treatment in 2014 (http://
apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.
pdf).
These guidelines acknowledge the many barriers to implemen-
tation in low- and middle-income countries (LMIC). However, the
most profound barrier to accessing treatment for hepatitis C glob-
ally, including in high-income countries, is the exorbitant prices of
new DAAs (over US$100,000 per treatment course in the United
States). We have learned important lessons about how to ensurethat HIV-infected patients from LMIC do not die unnecessarily
from eminently treatable infections. It is no longer a radical pro-
posal that governmental and nongovernmental agencies commit
to the provision of life-long treatment and care of people living
with HIV across the globe. We have the opportunity to translate
even more rapid advances in HCV drug development into the glob-
al eradication of this disease. This will depend on our ability to
match the level of public–private partnerships that have trans-
formed control of other global diseases. This paper will examine
some of the unmet medical needs in LMIC that would have to be
achieved to eliminate premature deaths due to complications of
hepatitis C.
An estimated 185 million people have been infected with HCV,
and over 80% live in LMICs (Mohd Hanaﬁah et al., 2013). Untreated
HCV infection leads to liver cirrhosis in up to a third of those who
are chronically infected and these individuals are at risk for com-
plications such as hepatocellular carcinoma (HCC) and hepatic
decompensation (Davis et al., 2010). Up to 500,000 people die each
year from complications secondary to HCV infection; most in LMIC
(Lozano et al., 2012).
Eradicating infection with hepatitis C is the most effective way
to reduce the incidence of liver decompensation and hepatocellular
carcinoma (HCC) (van der Meer et al., 2012). According to the US
Centers for Disease Control and Prevention (CDC), one premature
death is prevented for every three virological cures (Rein et al.,
90 C.S. Graham, T. Swan / Antiviral Research 119 (2015) 89–962012). Few medical interventions against chronic diseases can
match this number-needed-to-treat rate. In addition, reducing
the pool of infected people could signiﬁcantly decrease new infec-
tions and the overall prevalence of HCV infection in a community
(Martin et al., 2013b). Major challenges include diagnosing infect-
ed individuals, linking them into care and ensuring access to treat-
ment with DAAs.2. Who has HCV infection?
In high-income countries, HCV spread extensively in the 1940’s
and 1950’s (Japan) through the 1960’s to 1980’s (North America
and Western Europe) via contaminated blood supplies, poor infec-
tion-control practices during medical procedures, and injection
drug use, as well as other, less well deﬁned risks of community
acquisition (Nakano et al., 2004). Because of changes in injection
drug use and infection control practices with the advent of the
HIV epidemic and blood supply screening, HCV transmission has
signiﬁcantly decreased over the last 20 years in high-income
regions (Armstrong et al., 2006).
Low- and middle-income countries often have ongoing routes
of infection. Formal and informal medical care using unsafe injec-
tions or improperly sterilized medical equipment account for 40%
of global HCV infections (Hauri et al., 2004; Averhoff et al., 2012).
In addition, the WHO has found that 20% of surveyed countries
do not screen their blood supply for HCV.
With the exception of a few countries such as France, which
have instituted national viral hepatitis testing programs, accuracy
of the estimates of anti-HCV antibody prevalence in most regions
of the world is poor (Delarocque-Astagneau et al., 2010). In the
US, for example, estimates of the numbers of infected individuals
range from 3.2 million to over 6 million (Edlin, 2011; Holmberg
et al., 2013b). Many regional prevalence studies tested blood
donors or pregnant women, neither of whom may be representa-
tive of the broader population of individual countries (Mohd
Hanaﬁah et al., 2013). A recent meta-analysis of global HCV sero-
prevalence that used data from general population surveys esti-
mated that there are >180 million people with anti-HCV
antibodies, and over 100 million are in South and East Asia
(Mohd Hanaﬁah et al., 2013). This study also highlighted regions
with very limited seroprevalence data, including the Caribbean,
Central Asia, Andean Latin America, and Central Sub-Saharan
Africa. Surveys of immigrant populations in high-income countries
are consistent with a high prevalence of anti-HCV antibodies and
complications of infection in LMIC. For example, a survey of
Somali versus non-Somali patients at a clinic in Minnesota, USA
found anti-HCV antibody prevalence rates of 9.9% and 6.6% in
Somali men and women, respectively, compared to rates of 3.2%
and 1.7% in non-Somali male and female patients as well as high
rates of HCV-associated HCC in Somalis (Shire et al., 2012).
Risk-based testing performs poorly as a strategy to identify peo-
ple who have been exposed to HCV, as evidenced by up to 85% of
people in the United States who are unaware of their diagnosis
in spite of recommendations in place since 1998 to test people
with well characterized risk factors (Mitchell et al., 2010; Smith
et al., 2012). This is likely due to stigma around certain risk behav-
iors such as injection drug use and lack of knowledge about the risk
of certain exposures, such as receipt of blood products years ago or
exposure to medical procedures prior to effective infection control
practices. The United States recently recognized that 75% of people
with HCV infection were born from 1945 through 1965 because of
the dynamics of peak transmission during the 1960’s to 1980’s
(Smith et al. 2012). This has led to a recommendation to test every-
one in this birth cohort once. Interestingly, similar age-speciﬁc
peaks in seroprevalence of anti-HCV antibodies among the55–64 years age group are seen across the globe (Mohd Hanaﬁah
et al., 2013).
Progression to advanced ﬁbrosis is a function of duration of HCV
infection and current age, as well as factors that accelerate ﬁbrosis
such as excessive alcohol consumption and HIV coinfection. Men
tend to have higher infection rates and lower rates of spontaneous
clearance of acute infection, leading to a disproportionate burden
of advanced liver disease (it is estimated that 75% of the people
in the US with HCV infection and cirrhosis are men) (Davis et al.,
2010). To identify those most at risk for development of severe
complications of HCV infection, a global age-based HCV testing
program, adjusted for local epidemiology, would be a ﬁrst step to
identifying those people with more advanced liver disease who
are most likely to beneﬁt immediately from diagnosis and
treatment.3. What new diagnostic methods are needed for hepatitis C?
Most screening programs use an enzyme-linked immunoassay
to identify antibodies against HCV. The costs of these tests range
from US$10 to $25. Low-income countries are able to access lower
cost anti-HCV antibody tests, but there is little quality control or
assurance about test performance in speciﬁc countries. The WHO
hepatitis C guidelines suggest that countries that attribute much
of their HCV transmission to health-care settings may need to con-
sider screening the general population, which would require access
to high quality, inexpensive tests. Ideally, the costs for serological
tests should be similar to HIV serological tests, which are less than
US$ 1 per assay in low-income countries, since the total number of
people requiring testing for anti-HCV could approach 2 billion (Wu
and Zaman, 2012).
Fifteen to thirty percent of exposed persons will spontaneously
clear their acute HCV infection, so all persons with detected anti-
HCV antibodies need to undergo further testing to determine the
presence of virus and active infection. Examples of conﬁrmatory
tests include qualitative and quantitative HCV nucleic acid testing
(NAT) and core antigen detection assays. Unfortunately, conﬁrma-
tion of active HCV infection was only performed about 50% of the
time in a CDC survey of US cities and conﬁrmation is much lower
in many LMIC (Centers for Disease and Prevention, 2013). There
are substantial barriers to widespread implementation of NAT in
LMIC, including the requirement for rapid processing of whole
blood, cold storage of samples, expensive instruments and
reagents, trained technicians, and expense of the assays.
In certain countries of sub-Saharan Africa, there is an important
additional complexity. A relatively high percent of persons are
anti-HCV positive, yet HCV RNA negative. Table 1 provides an over-
view of recent studies that compared anti-HCV antibody preva-
lence with conﬁrmed NAT testing in sub-Saharan Africa.
Supplemental Table 1 has a more complete listing of studies and
includes results of quantitative HCV RNA testing. Few studies have
reported quantitative HCV RNA results, making it difﬁcult to deter-
mine the level of sensitivity future assays would require for detec-
tion of active HCV infection. The phenomenon of high rates of false
positive anti-HCV serological tests is true both for patients with
HCV mono-infection and HIV/HCV coinfection, and may be related
to cross-reactivity with endemic infectious agents. These ﬁndings
have substantial implications. Since serological rapid diagnostics
tests are less expensive than NAT, these are often used to screen
prospective blood donors, which can result in inappropriate exclu-
sion of uninfected donors in a region that already has the lowest
per-population rate of blood donation and the highest wastage of
donated units due to transmittable infectious diseases. (see
the 2013 WHO Global Report on blood safety for additional
details: http://www.who.int/bloodsafety/transfusion_services/WHO_
Table 1
Sub-Saharan African studies that compare prevalence of HCV infection by anti-HCV antibody and nucleic acid testing.
References Study population HCV assays performed Anti-HCV prevalence % (n) NAT detection in anti-HCV reactive samples %
(n)
Cantaloube et al.
(2010)
Republic of the Congo
Population-based
Ortho HCV 3.0 (ELISA Diagnostics systems) 5.6% (50/887) 62% (31/50)
Monolisa anti-HCV Plus v 2 (Bio-Rad)
Inno-Lia HCV Immunoassay (Innogenetics)
In-house PCR
Seremba et al. (2010) Uganda
Hospitalized patients
Rapid strip assay (Cortez Diagnostics) 5% (19/380 by RSA)
6.8% (26/380 by ADVIA)
13% (48/380 reactive by one or both
assays)
29% (14/48)
Advia Centaur HCV EIA (Siemens Diagnostics)
Branched DNA, Versant 3.0 (Siemens Diagnostics)
Amplicor PCR (Roche)
RIBA 3.0 (Chiron)
Abreha et al. (2011) Ethiopia
Voluntary testing and counseling
center
Murex anti-HCV v 4.0(Abbott-Murex Diagnostics) 3.63% (71/1954)
6.8% (50/734 HIV+)
1.7% (21/1220 HIV)
25.4% (18/71)
Abbott Real-time PCR (Abbott Molecular)
Zeba et al. (2011) Burkina Faso
Pregnant women
Acon HCV rapid test strips 2.14% (13/607)
2.38% (HIV+)
1.75% (HIV)
100% (13/13)
In-house PCR
Forbi et al. (2012) Nigeria
Population-based
Immuno-chromatographic rapid assay (Shantha
Biotechnics)
14.1% (73/519) 75.3% (55/73)
In-house PCR
Agbaji et al. (2013) Nigeria
HIV+ patients
Dia Pro EIA (Diagnostic Bioprobe) 18.3% (262/1431) 30.2% (79/262)
Cobas Amplicor HCV Monitor 2.0 (Roche)
Cable et al. (2013) South Africa
Blood donations
Prism chemoluminescent analyzer (Abbott Diagnostics) 0.12% (976 samples reactive by Prism)
51 samples reactive with Prism and Murex
1.5% (15/976)
29.4% (15/51)Murex EIA (Abbott Diagnostics)
In-house PCR
Iles et al. (2013) Democratic Republic of Congo
Male members of uniformed services
Ortho 3.0 Enhanced SAVe (Ortho Clinical Diagnostics) 13.7% (41/299) 26.8% (11/41)
In-house PCR
Mullis et al. (2013) Uganda
Rakai cohort
Ortho v 3.0 HCV EIA (Ortho Diagnostics) 7.6% (76/1000)
6.2% (31/500 in HIV+)
9.0% (45/500 in HIV)
0% (0/76)
Abbott Real-time PCR
Survey of recent studies that measured both hepatitis C seroprevalence and conﬁrmation of active infection with a nucleic-acid test in sub-Saharan Africa. The percentage of individuals in sub-Saharan Africa who have active
infection conﬁrmed by detection of HCV RNA after sero-reactive anti-HCV antibody tests is much lower than in other parts of the world. It is unclear whether these results represent immunological cross-reactivity with other
immunogens that are common in this region. The lack of speciﬁcity poses challenges for affordable HCV screening programs in sub-Saharan Africa.
Abbreviations used: HCV = hepatitis C virus; NAT = nucleic acid testing; PCR = polymerase chain reaction; EIA = enzyme immunoassay; RSA = rapid strip assay.
C.S.G
raham
,T.Sw
an
/A
ntiviral
R
esearch
119
(2015)
89–
96
91
92 C.S. Graham, T. Swan / Antiviral Research 119 (2015) 89–96GlobalStatusReportSelf-SufﬁciencyinBloodBloodProducts.pdf?ua=
1). Patients may have management decisions made about their
care without having true infection. Or, patients may progress to
advanced liver disease, because they were not tested due to mis-
trust in the results of available assays.
Globally, access to HCV NAT or direct viral antigen detection is
essential. Diagnostic companies should take up the challenge of
developing rapid, point-of-care assays for the detection of active
HCV infection in individuals that are in the price range of HIV viral
load or p24 antigen tests in low-income countries. Preferably, the-
se assays will require minimal sample processing and allow perfor-
mance at room temperature. The academic community in these
countries can help deﬁne how sensitive these assays need to be,
since there may be a balance between sensitivity and cost. A
qualitative assay that can detect the equivalent of at least
1000 IU/mL HCV RNA may be sufﬁcient for most management pur-
poses and participants in a collaboration organized by the
Foundation for Innovative New Diagnostics and the Forum for
Collaborative HIV Research have started work on a diagnostic tar-
get product proﬁle (November 11, 2014). Ultimately, a single
qualitative assay that directly detects the presence of HCV could
be used to diagnose active infection and conﬁrm cure after antivi-
ral treatment since the additional information from a quantitative
HCV RNA value will likely not impact any clinical management
decisions in the era of DAAs.
Global agencies and foundations should encourage and support
development of low-cost, point-of-care, polyvalent platforms that
can perform direct viral testing for HCV as well as HIV and hepatitis
B virus (HBV), since co-infection with these viruses is common in
many regions of the world. Cross-platform testing capacity would
minimize the possibility that resource-limited settings would have
to invest in multiple analyzer platforms or be forced to choose
which infections to diagnose.4. Staging liver disease
As treatments improve, the distinction between stage 0 and
stage 1 or 2 liver ﬁbrosis will have little impact on patient manage-
ment. However, it will be important to distinguish mild to moder-
ate ﬁbrosis from advanced ﬁbrosis (bridging ﬁbrosis or cirrhosis).
Those with advanced ﬁbrosis are more likely to develop complica-
tions in the near future, which drive urgency to treat as well as the
need for disease management interventions such as screening for
HCC. There are a number of non-invasive ﬁbrosis markers that
use commonly acquired laboratory values and patient characteris-
tics to calculate scores. The United States Preventive Services Task
Force performed an extensive review of scoring systems and found
that the age-platelet index and APRI (which uses AST and platelets)
were moderately useful for diagnosing cirrhosis (Chou and
Wasson, 2013). FIB-4 (which uses ALT, AST, age and platelet count)
also has a high correlation with liver ﬁbrosis stage by biopsy
(Holmberg et al., 2013a). These serum biomarker panels are
relatively inexpensive and can be repeated annually to detect liver
ﬁbrosis progression and determine who needs additional manage-
ment of cirrhosis.5. Eliminate ongoing HCV transmission
Of the estimated 3–4 million annual new cases of HCV infection
each year, unsafe healthcare practices, such as unscreened blood
products or reused syringes, account for over 2 million of these
infections (Maheshwari et al., 2008). At a minimum, LMIC need
support to eliminate healthcare-associated HCV transmission.
Inexpensive diagnostic tests to determine the presence of HCV
RNA are needed to screen the blood supply in every country. Thesensitivity of NAT for ensuring the lack of infectivity of the blood
supply will be lower than that needed for clinical management,
but this setting may be more amendable to higher-volume
approaches like pooling samples. There should be separate regula-
tory pathways for evaluation of HCV diagnostics for clinical man-
agement and screening of blood products.
A modeling study in India found that the fraction of HCV infec-
tions attributed to unsafe medical injections was 38% (Reid, 2012).
In this study, universal use of auto-disposable syringes was found
to be a cost-effective alternative to reused syringes. Studies such as
this may help stimulate needed public–private investment in
health care infrastructure to minimize avoidable iatrogenic trans-
mission risks.
Inadequate access to sterile injection equipment, criminaliza-
tion and other barriers are driving the HCV epidemic among people
who inject drugs (PWID). Most ongoing HCV transmission in high-
and middle-income countries, and some in low-income countries
is attributed to injection drug use with unsterilized equipment
(Grebely and Dore, 2014). Martin and colleagues have performed
elegant analyses demonstrating that treating a small proportion
of PWID in combination with high-coverage needle and syringe
exchange programs and opioid substitution treatment can
decrease the population level prevalence rate of HCV (Martin
et al., 2013a,b). Harm reduction interventions are also needed for
primary prevention, to reduce the incidence of reinfection, and to
maintain the beneﬁts of antiviral treatment. These approaches will
require a global acknowledgment of human rights for PWID, their
involvement in program design, implementation and oversight,
and government-level support of harm reduction and medical
intervention programs.
Many PWID will enter prisons and other detention facilities at
some point, creating risks for ongoing transmission to other detai-
nees as well as opportunities for prevention and treatment. A
recent meta-analysis estimated that 2.2 million detainees (26% of
general detainees) globally are anti-HCV antibody positive, with
over half in North America and East and Southeast Asia (Larney
et al., 2013). Global eradication of hepatitis C will require a human
rights-based, logical approach to prevention, diagnosis and treat-
ment in these detained populations.
A vaccine strategy for the prevention of hepatitis C in high-risk
populations including PWID may ultimately be the most effective
means of eliminating incident HCV infections. The technical chal-
lenges associated with developing an effective vaccine against a
virus with such sequence variation are daunting, although an ini-
tial HCV vaccine trial has been initiated (Cox and Thomas, 2013;
Drummer, 2014).6. Applying lessons from HIV to access for antiviral medications
against HCV
In the last decade, multiple interventions have increased access
to life-saving antiretroviral treatment (ART) for suppression of HIV.
The number of individuals on ART has dramatically increased in
LMIC and it is estimated that nearly 10 million people are receiving
ART for as little as $100 per person annually (Jayasekera et al.,
2014). This effort represents a commitment from the world com-
munity to provide life-long treatment. We can learn lessons from
interventions that have worked well, and areas that still need
improvement in order to accelerate access to drugs against hepati-
tis C in LMIC. An excellent analysis of access to HIV, TB and HCV
drugs in resource-limited settings was published by the
Treatment Action Group and HIV i-Base (see Table 2: resources
for understanding hepatitis C treatment access). These authors
note that access to affordable ART for HIV infection began with
the mobilization of civil society to demand a human rights-based
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C.S. Graham, T. Swan / Antiviral Research 119 (2015) 89–96 93approach to treatment access. Inter-governmental agencies and
foundations such as The Global Fund to Fight AIDS, Tuberculosis
and Malaria, The Clinton Health Access Initiative, the United
States President’s Emergency Plan for AIDS Relief, and UNITAID
began market shaping, pooling demand and large-scale purchase
of ART and diagnostics as well as funding for the delivery of care.
Additional mechanisms have been used to increase the afford-
ability of HIV medications, including generic competition, volun-
tary licensing, tiered pricing, and the Medicines Patent Pool.
Some governments have used TRIPS (trade-related aspects of intel-
lectual property rights) ﬂexibilities to increase access to affordable
ART via generic production of patented medications. Regulatory
approval in LMIC has been expedited by broadening the tentative
approval system of the US Food and Drug Administration, con-
tinuing the WHO Prequaliﬁcation Program, and expanding the
European Medicines Agency’s use of article 58 (a program which
allows the EMA to provide a scientiﬁc opinion on certain vaccines
and drugs intended for markets outside of the European Union) to
help encourage regulatory modernization and minimize unneces-
sary duplication of efforts (see Table 2 for resources addressing
access to HCV treatment using strategies that have been successful
in HIV).
There are many beneﬁts to identifying people who are infected
with HCV including counseling around reducing or eliminating
alcohol consumption, identifying who has cirrhosis and initiating
screening for HCC and gastroesophageal varices, providing vacci-
nations for hepatitis A and B in those not previously exposed,
and providing harm reduction counseling that may decrease the
risk of HCV reinfection and transmission to others. However, the
most signiﬁcant way to reduce the incidence of diseases associated
with HCV infection is to achieve virological cure.
In recognition that treatment is a necessary component of any
eradication strategy, the WHO added pegylated interferon alfa
(Peg-IFN) to the list of essential medications in 2013. However,
Peg-IFN is unequivocally less effective, more toxic and difﬁcult to
administer than the DAAs. One of the ethical challenges in ART
delivery in LMIC has been the use of more toxic antiretroviral
agents long after they ceased being used in high-income countries.
Forcing LMIC to use interferon-base therapy while high-income
countries have transitioned to all-oral regimens repeats this same
mistake. It is now possible for all countries to leap-frog the inter-
feron era and go directly to DAA-based treatment.
Agreements that will result in at least a 100-fold reduction in
the US price of some DAAs are already being announced. Egypt,
which has the highest prevalence of HCV infection in the
world, has negotiated access to sofosbuvir at a cost of US$900
for 12 weeks (http://www.reuters.com/article/2014/03/21/us-
hepatitis-egypt-gilead-sciences-idUSBREA2K1VF20140321; accessed
7/10/14). In September 2014, Gilead announced licensing
agreements with seven Indian companies to manufacture generic
hepatitis C medicines for 91 developing countries, tiered pricing
in developing countries as well as differential pricing for public
and private markets (http://www.gilead.com/~/media/Files/pdfs/
other/HCVGenericAgreementFactSheet.pdf). Bristol-Myers Squibb
has announced plans to work with licensed generic manufacturers
to supply licensed versions of daclatasvir in 90 developing coun-
tries (http://www.bms.com/responsibility/access-to-medicines/
Pages/HCV-developing-world-strategy.aspx). It remains to be seen
whether generic competition will lower DAA prices to affordable
levels in each of these countries, and in both public and private
markets. In the excluded middle-income countries – home to mil-
lions of people with hepatitis C – no generics will be available, and
prices will be set by pharmaceutical companies; widespread
affordability is unlikely.
Mounting a response to epidemics in middle-income coun-
tries is complicated by the perception that MIC – as opposed to
94 C.S. Graham, T. Swan / Antiviral Research 119 (2015) 89–96low-income countries-are emerging markets for pharmaceutical
products at premium pricing. In actuality, the ‘‘bottom billion’’ –
960 million, or 72% of the world’s poorest people, deﬁned as less
than US$1.25 per capita/day – live in MICs (http://www.ids.ac.
uk/ﬁles/dmﬁle/Wp349.pdf). Access to health care and medicines
varies widely across MICs and up to 90% of patients in MIC pay
for medications out of pocket. Some countries have insurance
schemes, but these do not always cover HCV treatment, diagnostic
tests, or monitoring. Tiered pricing – selling medicines at different
prices to improve access while generating revenue for the pharma-
ceutical industry – is unlikely to address treatment access in MICs.
The criteria for tiered pricing is based solely on per capita gross
national income (GNI) from the World Bank, leaving poor and
uninsured people in MICs without access to affordable medicines
(Moon et al., 2011). Ultimately, all countries must have affordable
drug pricing across the population if they are to provide treatment
for HCV infection. The actual production costs for a 12-weeks DAA
regimen is estimated at less than US$250, so this should be an
achievable goal (Hill et al., 2014) (see Table 2).
The only economic value gained from treating HCV infection is
if virological cure is achieved, with potential reduction in future
costs of HCV-related complication. There is no evidence that
unsuccessful therapy is of any beneﬁt to patients (Di Bisceglie
et al., 2008). It is helpful to analyze total costs per cure, which takes
into account all the costs associated with treating HCV infection
with a speciﬁc regimen as well as the cure rate. For example, treat-
ment costs can include the price paid for each component of a
combination regimen as well as laboratory monitoring, clinic visits,
medications used to manage adverse events, hospitalizations relat-
ed to treatment complications, and quality of life impact. Regimens
that have higher drug prices but require less monitoring and have
higher cure rates may have a lower cost per cure.
Government funded medication programs will need coordina-
tion between advocates, academic centers and health policy agen-
cies to prioritize hepatitis C diagnosis and treatment strategies.
Countries should determine the prevalence of HCV seropositivity,
active infection (using HCV NAT or core antigen testing), rates of
advanced liver disease complications and hepatitis C-related mor-
tality, and costs associated with HCV infection in their population.
An example of a model that used a country-speciﬁc willingness-
to-pay threshold to determine the cost effectiveness of birth cohort
screening for HCV was performed by the CDC (Rein et al., 2012).
These analyses showed that in the US, screening the 1945–1965
birth cohort was as cost effective as a number of other interven-
tions that have been determined to be cost effective, such as hyper-
tension or cervical cancer screening. Alternatively, a model that
starts with a product’s public health beneﬁt, cost-beneﬁt ratio
and cost off-sets to derive a price that represents the value of a
drug or regimen in a speciﬁc country may be a more objectiveTable 3
Example of minimal patient-level HCV management and treatment. In order to eradicate
active infection should be streamlined and made available in LMIC. The use of affordable, p
diagnostic tests such as HCV genotype assays and precise determination of liver ﬁbrosis s
Need Intervention
HCV screening Point of care serologic test
Conﬁrmatory HCV testing Qualitative HCV RNA test or
similar sensitivity
Screen for advanced ﬁbrosis/cirrhosis FIB-4 and clinical exam
Screen for HCC and gastroesophageal varices in
cirrhotic patients
Liver ultrasound every six m
3 years
Antiviral treatment Sofosbuvir plus daclatasvir
Determine sustained virological response 24 weeks
after completion of treatment
Qualitative HCV RNA test or
minimum threshold of 1000way to ensure affordability (Lopert et al., 2002). High-income
countries such as the United Kingdom, Canada, and Australia use
similar methodologies for determining national prices and should
share models so consistent national data are collected among
countries.
Choosing an antiviral treatment regimen and determining the
duration of treatment has been dependent on HCV genotype with
Peg-IFN + RBV, the ﬁrst generation protease inhibitors, and some of
the all-oral regimens in development. However, regimens that can
be broadly used in LMIC should be pan-genotypic. We already have
an example of a pan-genotypic regimen, the combination of sofos-
buvir and the NS5a inhibitor, daclatasvir (Wang et al., 2014). This
combination is currently being studied in genotypes 1, 2, 3, 4, 5,
and 6, in patients with compensated and decompensated cirrhosis,
HIV/HCV coinfection, and those who have failed previous Peg-IFN
and RBV plus telaprevir or boceprevir (see trial descriptions in
clinicaltrials.org). A regimen such as this could minimize total test-
ing requirements for treatment and management (see Table 3).
Although HIV coinfection accelerates liver disease progression
in persons with HCV infection, drug development and access to
treatment have lagged behind for persons with HIV/HCV coinfec-
tion even though preliminary data from clinical trials of DAA-based
treatment show very similar SVR rates to those in HCV mono-
infected persons (Rockstroh and Bhagani, 2013). Established HIV
treatment programs in LMICs offer an opportunity to deliver care
and treatment to coinfected individuals, leveraging the existing
work force and laboratory monitoring platforms.7. Monitoring treatment and ensuring adherence
It is anticipated that future treatment regimens for HCV infec-
tion will be 12 or fewer weeks in duration. Integrated programs
should follow models such as one developed by the WHO for their
Stop TB campaign, which addresses diagnostic needs, access to
medications, adherence support, and protection of human rights
(http://www.who.int/tb/strategy/stop_tb_strategy/en/). Once access
to hepatitis C treatment is established, the likely real-world limita-
tions to SVR rates over 90% will be maintaining supply chain and
individual adherence rates. Adherence interventions such as
directly-observed therapy or electronic reminders could be consid-
ered for regimens that take 12 or fewer weeks to complete, par-
ticularly with ﬁxed-dose combinations and single-tablet
regimens. Models to expand the pool of qualiﬁed providers in
regions with inadequate numbers of HCV specialists can emulate
training and expansion projects for HIV or TB care. It would be in
the best interest of institutions that are funding treatment to invest
in additional adherence and support programs such as peer sup-
port, directly observed therapy, text reminders, home visits, orhepatitis C infection in LMIC, each step in screening, diagnosis, and management of
an-genotypic antiviral regimens would obviate a number of expensive and/or complex
tage.
Comments
For widespread population-based screening, cost
needs to be <US $1 a day
HCV antigen test with For most patients a minimum threshold of 1000 IU/
mL will be sufﬁcient
FIB-4 uses commonly available ALT, AST, age and
platelet count
onths; EGD every 1– May not be available in all countries
Pan-genotypic, no response-guided therapy
HCV antigen test;
IU/mL
Establish cure. If not cirrhotic, then patients go back
into general medical care
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C.S. Graham, T. Swan / Antiviral Research 119 (2015) 89–96 95electronically monitored pill administration or blister packaging to
maximize the beneﬁt of this ﬁxed-duration treatment. See Table 4
for a summary of speciﬁc actions that can be taken by public and
private organizations to improve the diagnosis and treatment of
people living with HCV infection.
8. Conclusion
Low- and middle-income countries, which carry the global bur-
den of HCV disease, should not be abandoned as high-income
countries enter a new era of highly effective, all-oral, shorter dura-
tion, yet very expensive therapy for the cure of HCV infection.
World-wide pressure helped create the regulatory and pricing
changes that allowed millions to access life-saving HIV treatment,
even though this required a commitment to life-long treatment.
We need the same level of advocacy to reduce the number of pre-
mature deaths from HCV-associated complications in all countries,
and short-duration treatment that can result in cure of hepatitis C
infection should make this goal even more achievable than world-
wide control of HIV infection. However, only providing access to
more affordable medications is not enough. As stated in the
WHO HCV Guidelines, ‘‘The opportunity to address the massive
HCV pandemic is now within reach and a global movement is
needed to create generalized access to HCV treatment in high-,
middle- and low-income countries. This will require political will,
ﬁnancial investment, and support from pharmaceutical, medical
and civil society organizations around the world’’.
We are beginning to see the broad outlines of what this global
movement could look like and we hope that one day these
approaches to hepatitis C will be held as models for future global
health efforts.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.antiviral.2015.01.
004.
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